Form
SCHEDULE 13D/A
Active or control-oriented beneficial ownership filing.
BIOS Fund II, LP - 02 May 2025 SCHEDULE 13D/A Report for IN8bio, Inc. Common Stock, par value $0.0001 per share (INAB)
- Filing manager
- BIOS Fund II, LP
- Reporting owner
- BIOS CAPITAL MANAGEMENT, LP
- Beneficially owned shares
- 9,120,073 shares
- Large-stake signal
-
Ownership
10%Beneficial ownership of this reported class.
Shares
9,120,073 sharesShares beneficially owned as disclosed.
Event date
02 May 2025Date tied to the ownership event or amendment.
Accepted by SEC
08 May 2025EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 10%
- Symbol
- INAB
- Shares outstanding
- 91,292,022 shares
- SEC form
- SCHEDULE 13D/A
- Accepted by SEC
- 08 May 2025, 17:53:02 UTC
- Event date
- 02 May 2025
- Next SEC filing
- 29 Dec 2025
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
5 source fields
Key filing fact
BIOS Fund II, LP disclosed 10% ownership in IN8bio, Inc. Common Stock, par value $0.0001 per share (INAB) on 02 May 2025.
Key facts
- BIOS Fund II, LP filed SCHEDULE 13D/A for IN8bio, Inc. Common Stock, par value $0.0001 per share (INAB).
- Disclosed ownership: 10%.
- Date of event: 02 May 2025.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 08 May 2025, 17:53.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (19)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BIOS FUND II, LP | 0.6% | 574,432 | 0 | 574,432 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001714576 |
| BIOS FUND II QP, LP | 2.1% | 1,876,624 | 0 | 1,876,624 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001716869 |
| BIOS FUND II NT, LP | 0.3% | 251,211 | 0 | 251,211 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001728851 |
| BIOS INCYSUS CO-INVEST I, LP | 1.1% | 997,433 | 0 | 997,433 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001740029 |
| BIOS FUND III, LP | 0.6% | 570,724 | 0 | 570,724 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001791917 |
| BIOS FUND III QP, LP | 4.1% | 3,727,597 | 0 | 3,727,597 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001791916 |
| BIOS FUND III NT, LP | 0.7% | 601,980 | 0 | 601,980 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001791910 |
| BIOS CLINICAL OPPORTUNITY FUND, LP | 3.3% | 3,140,803 | 3,140,803 | 0 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001988639 |
| BP DIRECTORS, LP | 0.1% | 121,775 | 0 | 121,775 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001813311 |
| BIOS EQUITY PARTNERS, LP | 0.1% | 121,775 | 0 | 121,775 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001813314 |
| BIOS EQUITY PARTNERS II, LP | 4.1% | 3,699,700 | 0 | 3,699,700 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001813313 |
| BIOS EQUITY PARTNERS III, LP | 5.4% | 4,900,301 | 0 | 4,900,301 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001831976 |
| BIOS EQUITY COF, LP | 3.3% | 3,140,803 | 3,140,803 | 0 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0002000747 |
| CAVU MANAGEMENT, LP | 9.6% | 8,721,776 | 0 | 8,721,776 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001813270 |
| BIOS CAPITAL MANAGEMENT, LP | 10% | 9,120,073 | 0 | 9,120,073 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001813845 |
| CAVU ADVISORS, LLC | 9.6% | 8,721,776 | 0 | 8,721,776 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001813310 |
| BIOS ADVISORS GP, LLC | 9.9% | 9,120,073 | 0 | 9,120,073 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001813844 |
| LESLIE W. KREIS | 9.6% | 8,721,776 | 0 | 8,721,776 | /s/ Daniel Schwarz | DANIEL SCHWARZ, as Attorney-in-Fact for Leslie W. Kreis, Jr. | 0001813316 |
| AARON G.L. FLETCHER | 10% | 9,120,073 | 0 | 9,120,073 | /s/ Daniel Schwarz | DANIEL SCHWARZ, as Attorney-in-Fact for Aaron G.L. Fletcher | 0001789490 |
CIK / CUSIP context first